Focusing on new monoamine oxidase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 7, 2010, Pages 909-939

  Bolasco, Adriana ^a   Carradori, Simone ^a   Fioravanti, Rossella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Depression; MAO inhibitor; Neuroprotection; Parkinson's disease

Indexed keywords

AMIDE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE DERIVATIVE; APORPHINE DERIVATIVE; BENZOPYRAN DERIVATIVE; BENZYL DERIVATIVE; BETA CARBOLINE DERIVATIVE; BIPHENYL DERIVATIVE; CLORGYLINE; DITERPENE; IMIDAZOLE DERIVATIVE; INDAN DERIVATIVE; IPRONIAZID; ISOCARBOXAZID; ISOXAZOLE DERIVATIVE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OXAZOLIDINONE DERIVATIVE; PHENELZINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RASAGILINE; SAFINAMIDE; SELEGILINE; SULFONAMIDE; UNINDEXED DRUG;

BRAIN FUNCTION; BRUXISM; CHRONIC TENSION HEADACHE; COGNITION; DEGENERATIVE DISEASE; DEGRADATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; EMOTION; ENZYME INHIBITION; GLAUCOMA; HUMAN; MIGRAINE; MITOCHONDRION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SHY DRAGER SYNDROME; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; MENTAL DISORDERS; METABOLISM; PATENT; PATHOPHYSIOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PATENTS AS TOPIC;

EID: 77953743826     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.495716     Document Type: Review

References (142)

1. Singer TP, Von Korff RW, Murphy DL. Monoamino oxidase: structure, function and altered functions. Academic: New York; 1979
2. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 1998;5:137-162
3. Da Prada M, Kettler R, Keller HH, et al. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl 1990;29:279-292
4. Strolin-Benedetti M, Dostert PL. Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Adv Drug Res 1992;23:65-125
5. Hubalek F, Binda C, Khalil A, et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 2005;280(16):15761-15766 Data deposition: www.pdb.org (PDB ID code 2BK3)
6. Son SY, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-A° resolution: the control of opening the entry for substrates/ inhibitors. Proc Natl Acad Sci USA 2008;105:5739-5744 Data deposition: www.pdb.org (PDB ID code 2Z5X)
7. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem 2004;11:925
8. Fowler JS, Logan J, Azzaro AJ, et al. Reversible inhibitors of Monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010;35(3):623-631
9. Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Design 2004;10(25):3167-3175
10. Drukarch B, Muiswinkel FL. Drug treatment of Parkinson's disease. Biochem Pharmacol 2000;59:1023-1031
11. Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 2006;4(4):330-346
12. Youdim MBH, Gross A, Finberg JP. Rasagiline [N-propagyl-1R-(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132(2):500-506
13. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004;18(12):1471-1473 and references therein
14. Blandini F, Armentero MT, Fancellu R, et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004;187(2):455-459
15. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67:S18-23
16. Zhang S-H, Blech-Hermoni Y, Faravelli L, Seltzer Z. Ralfinamide administered orally before hind paw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behaviour in the rat. Pain 2008;139(2):293-305
17. Van der Schyf CJ, Geldenhuys WJ, Youdim MBH. Multifunctional drugs: ladostigil, an anti-Alzheimer drug. In: Ana Martinez, editor, Medicinal Chemistry of Alzheimer's Disease. Transworld Research Network, Kerala, India; 2008. p. 1-20
18. Bolasco A, Fioravanti R, Carradori S. Recent development of Monoamine oxidase inhibitors. Exp Op Ther Patents 2005;15(12):1763-1782
19. Consejo Superior de Investigaciones Cientificas, ES. Preparation and Monoamino oxidase inhibition of beta-carboline from natural products. WO2007085679; 2007
20. Kim H, Sablin SO, Ramsay RR. Inhibition of monoamino oxidase A by beta carboline derivatives. Arch Biochem Biophys 1997;337:137-142
21. Nelson DL, Herbert A, Petillot T, et al. [3H]Harmaline as a specific ligand of MAO-A from rat and bovine brains. J Neurochem 1979;32(6):1817-1827
22. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005;326:378-386
23. Matsumoto T, Suzuki O, Furuta T, et al. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem 1985;18:126-129
24. Teva Pharmaceutical Industries, Ltd. Preparation of (propargylated) aminoindans as monoamine oxidase and acetylcholinesterase inhibitors for treatment of psychiatric and neurological disorders. US2007203232; 2007
25. Helicon Therapeutics, Inc. Preparation of isoxazole compounds as monoamine oxidase B inhibitors. WO2009029632; 2009
26. Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 1992;106:274-285
27. Van der Schyf CJ, Geldenhuys WJ, Youdim MBH. Multifunctional drugs: Ladostigil, an anti-Alzheimer drug. In: Medicinal Chemistry of Alzheimer's Disease. Ana Martinez, editor, Transworld Research Network, Kerala, India; 2008. p. 1-20
28. Dsm Ip Assets B.V. Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression. EP1925302; 2008
29. Cui YX, Xiao Q, Tu PF. A concise approach to the synthesis of carnosic acid type diterpenes. Chin Chem Lett 2001;12(3):203-204
30. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-732
31. Poling A, Cleary J, Monaghan M. Burying rats in response to aversive and nonaversive stimuli. J Exp Anal Behav 1981;35:31-44
32. Crawley AJN. Neuropsychopharmacological specifity of a single animal model for the behavioural action of benzodiazepines. Pharmacol Biochem Behav 1981;15:695-699
33. Bayer Pharmaceuticals Corp. Imidazole derivatives for the treatment of psychiatric disorders. WO2006060202; 2006
34. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonist in a maze-exploration model of fear-motivated behavior. Naunyn-Schmiedeberg's Arch Pharmacol 1984;327:1-5
35. Solvay Pharmaceuticals B.V. Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission. WO2006089861; 2006
36. Christen MO. Anetole dithiolenthione: biochemical considerations. Methods Enzymol 1995;252:316-323
37. Zhou M, Panchuk-Voloshina N. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal Biochem 1997;253:169-174
38. Universidade de Santiago de Compostela, ES. Use of oxoisoaporphines and the derivatives thereof as selective inhibitors of monoamino oxidase A. WO2009034216; 2009
39. Shamma M, Slusarchyk WA. The aporphine alkaloids. Chem Rev 1964;64:59-79
40. Bembenek ME, Abell CW, Chrisey LA, et al. Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-,3,4-dihydro- and fully aromatic isoquinolines. J Med Chem 1990;33:147-152
41. Yanez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Comm 2006;344:688-695
42. Glaxo Group Limited. Prolinamide derivatives as sodium channel modulators. WO2007042250; 2007
43. Janssen Pharmaceutica, N.V. Preparation of benzo-heteroaryl sulfamide derivatives for the treatment of depression. US2007191449; 2007
44. Janssen Pharmaceutica N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety disorders. WO2009120189; 2009
45. Malatynska E, Knapp RJ. Dominant-submissive behavior as models of mania and depression. Neurosci Biobehav R 2005;29:715-737
46. Aron C, Simon P, Larousse C, Boissier JR. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacol 1971;10:459-469
47. Orchid Research Laboratories Limited. MAO-A inhibitors with a diphenyl ether-substructure for treatment of mental disorders. WO2009030968; 2009
48. Ache Laboratorios Farmaceuticos S/A. Pharmaceutical compositions comprising benzopyranones for treating diseases and disturbances associated to monoamine oxidase. WO2009121155; 2009
49. Newron Pharmaceuticals S.p.A. Preparation of substituted aminoalkyl- and amidoalkyl-benzopyran derivatives as selective and reversible MAO-B inhibitors. WO2006102958; 2006
50. Dsm Ip Assets B.V. Novel agents for preventing and treating disorders connected to impaired neurotransmission. WO2006042441; 2006
51. Catto M, Nicolotti O, Leonetti F, et al. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. J Med Chem 2006;49:4912-4925
52. Carotti A, Altomare C, Catto M, et al. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. Chem Biodivers 2006;3:134-149
53. Chimenti F, Secci D, Bolasco A, et al. Synthesis, molecular modelling and selective inhibitory activity against human monoamine oxidases of 3-carboxamido substituted coumarins. J Med Chem 2009;52:1935-1942
54. Koorbanally NA, Randrianarivelojosia M, Mulholland DA, et al. Bioactive constituents of Cedrelopsis microfoliata. J Nat Prod 2002;65:1349-1352
55. Bohlmann F, Franke H. Isolation of obliquin from Phaenocoma prolifera. Phytochemistry 1973;12:726-727
56. Concert Pharmaceuticals, Inc. Preparation of alpha-amino amide derivatives for treatment of disease. WO2009054964; 2009
57. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half life approach and nonspecific binding to microsomes. Drug Metab Disp 1999;27:1350-1359
58. Bayer Pharmaceuticals Corp. Pyrazole derivatives for the treatment of psychiatric disorders. WO2006060201; 2006
59. Helicon Therapeutics, Inc. Preparation of substituted pyrazoles as MAO-B inhibitors. US2007203154; 2007
60. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 1998;24:285-301
61. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharm Biochem Behav 1986;24:525-529 (Pubitemid 16145187)
62. Fujifilm Finechemicals Co., Ltd. Preparation of pyridine derivatives as MAO inhibitors and pharmaceutical compositions containing them. JP2008239520; 2008
63. Fujifilm Corp. Pyridine analogs with blood brain barrier permeability. JP2009249346; 2009
64. Roshchin VI, Sultanov VS. Medicinal agent for treating patients suffering from diseases caused by the monoaminooxidase excessive activity and a method for treating patients suffering from diseases caused by the monoamine oxidase excessive activity. RU2366430; 2009
65. Merck Frosst Canada, Ltd. Preparation of aryl derivatives as reversible inhibitors of monoamine oxidase a and b. WO2006133559; 2006
66. Hoffman-La Roche, Inc. Preparation of benzyloxyphenoxyalkylcarboxamides and related compounds as monoamine oxidase-B inhibitors. US2005288367; 2005
67. Hoffmann-La Roche, Inc. Preparation of 1-(4-benzyloxyphenyl)pyrrolidin-2- one derivatives as monoamine oxidase B inhibitors. US2006025599; 2006
68. Hoffmann-La Roche AG. Process for preparing 4-pyrrolidinylphenyl benzyl ether derivatives as MAO-B inhibitors. WO2006097197; 2006
69. Astrazeneca AB. Preparation of 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl)-5-triazol-1-ylmethyloxazolidin-2- ones as MAO inhibitors for the treatment of bacterial infection. WO2005116024; 2005
70. Ferrer Internacional, S.A. [Fluoro(cyanopiperidinyl)phenyl] oxazolidinone as monoamine oxidase inhibitor and its preparation, pharmaceutical compositions and use in the treatment of bacterial infections. WO2009077484; 2009
71. Ferrer Internacional, S.A. {[(2)H-Tetrazol-5-yl]phenyl} oxazolidinones as monoamine oxidase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections. WO2009077485; 2009
72. Auspex Pharmaceuticals, Inc. Preparation of deuterated oxazolidinones with improved metabolic, pharmacodynamic, and toxicity properties for treatment of muscle skeletal disorders. WO2009132119; 2009
73. Pharmacia & Upjohn Company LLC. Substituted 2,3,5-trifluorophenyl oxazolidinones for use as antibacterial agents. WO2005113520; 2005
74. Astrazeneca AB. Preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3- triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents. WO2005116022; 2005
75. Dostert P, Strolin-Benedetti M, Guffroy C. Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236. J Pharm Pharmacol 1983;35:161-165
76. Gates KS, Silverman RB. Model studies for the mechanism of inactivation of monoamine oxidase by 5-aminomethyl-3-aryl-2-oxazolidinones. J Am Chem Soc 1989;111:8891-8895 and reference therein
77. Hauck SI, Cederberg C, Doucette A, et al. New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics. Bioorg Med Chem Lett 2007;17:337-340
78. Park C-H, Brittelli DR, Wang CL-J, et al. Antibacterials. Synthesis and structure-activity studies of 3-aryl-toxooxazolidines. 4. Multiply-substituted aryl derivatives. J Med Chem 1992;35:1156-1165
79. Flaherty P, Castagnoli K, Wang Y-X, Castagnoli Jr N. Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl- 1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl. J Med Chem 1996;29:4756-4761
80. Tan AK, Weyler W, Salach JI, Singer TP. Differences in substrate specificities of monoamine oxidase A from human liver and placenta. Biochem Biophys Res Commun 1991;181:1084-1088
81. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004;26(9):1355-1367
82. Weyler W, Salach JI. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 1985;260:13199-13207
83. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998;31(5):187-192
84. Auspex Pharmaceuticals, Inc. Preparation and utility of deutero-substituted amphetamines useful in the treatment of trauma, post-traumatic-stress-disorder and psychological disorders. WO2008016677; 2008
85. Auspex Pharmaceuticals, Inc. Deuterium-substituted tadalafil as PDE-5 inhibitors and their preparation and use in the treatment of PDE-5-mediated diseases. WO2007146124; 2007
86. Universitaet Tuebingen. Preparation of fluoroamphetamines as antiparkinsonian agents. WO2008113565; 2008
87. Schmidt WJ, Mayerhofer A, Meyer K, Kovar K. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neuroscience Lett 2002;330:251-254
88. Kirton & Mcconkie. Methods and compositions for inhibiting monoamine oxidase and catechol-O-methyltransferase. US2005202109; 2005
89. Rojas Castaneda P. Novel use of Gingko biloba extract for treating Parkinson's disease. WO2006004386; 2006
90. Vitaplant AG. Tannin-free extract of Rhodiola rosea. WO2008009151; 2008
91. Hong Kong Jockey Club Institute of Chinese Medicine Ltd. Antidepressant formulations comprising the extracts of Psoralea corylifolia and Poria cocos. US2006147569; 2006
92. Kong LD, Tan RX, Woo AY, Cheng CH. Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol 2001;88(2):75-80
93. Schurr A, Livne A. Different inhibition of mitochondrial monoamine oxidase from brain by hashish components. Biochem Pharmacol 1976;25:1201-1203
94. Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa. J Ethnopharmacol 2002;83:161-165
95. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985;85:367-370
96. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997;134:319-329
97. Huazhong Agricultural University, Peop. Rep. China. New formulations of Lotus proanthocyanidins for treating Alzheimer's disease. CN1943570; 2007
98. Oxford Pharmaceutical Services, Inc. Methods and pharmaceutical compositions using monoamine oxidase inhibitors for treating or preventing migraines. WO2007038675; 2007
99. Zogenix, Inc. Novel formulations for treatment of migraine. WO2009134336; 2009
100. Alcon Manufacturing, Ltd. Monoamine oxidase inhibitors useful for treating disorders of the outer retina. WO2008014457; 2009
101. Takahata K, Katsuki H, Kobayashi Y, et al. Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage. Eur J Pharmacol 2003;458(1-2):81-89
102. Buys YM, Trope GE, Tatton WG. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 1995;14(2):119-126
103. Reme C, Aeberhard B, Schoch M. Circadian rhythm of autophagy and light responses of autophagy, and disk-shedding in the rat retina. Trans Ophthalmol Soc UK 1983;103:405-410
104. Abler AS, Chang CJ, Fu J, et al. Photoic injury triggers apoptosis of photoreceptor cells. Res Commun Mol Path Pharmacol 1996;92:177-189
105. Overfield WD. Methods for preventing or treating bruxism using dopaminergic agents. US2009247537; 2009
106. Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy. WO2007098264; 2007
107. Wenning GK. Multiple System Atrophy. Lancet Neurol 2004;3(2):93-103
108. Cooper & Dunham, LLP. Method for the treatment of glaucoma using rasagiline. US2009062400; 2009
109. Farkas RH, Grosskreutz CL. Apoptosis, neuroprotection and retinal ganglion cell death: an overview. Int Opthalmol Clin 2001;41:111-130
110. Somerset Pharmaceuticals, Inc. Desmethylselegiline for treatment of cerebrovascular disease. WO2007117286; 2007
111. Knollema S, Aukema W, Hom H, et al. L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995;26(10):1883-1887
112. Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis. WO2006130726; 2006
113. University of Padua. Treatment of heart failure and associated conditions by administration of monoamine oxidase inhibitors. US2009286883; 2009
114. Bianchi P, Kunduzova O, Masini E, et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and post-ischemic myocardial injury. Circulation 2005;112:3297-3305
115. Youdim MBH, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 2004;25(1-2):243-250
116. Jenrin Discovery. Preparation of N-benzyl-N-propargyl-amines as MAO inhibitors for treatment of obesity. WO2008092091; 2008
117. Jenrin Discovery. MAO-B inhibitors useful for treating obesity. WO2007008963; 2007
118. Jenrin Discovery. MAO-B inhibitors useful for treating obesity. WO2006138475; 2006
119. McElroy JF, Chorvat RJ. MAO-B inhibitors useful for treating obesity. WO2006130707; 2006
120. L'Oreal, Fr. Use of inhibitors of monoamine oxidase for capillary pigmentation. FR2928545; 2009
121. Chu CY, Liu YL, Chiu HC, Jee SH. Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol 2006;154:1071-1079
122. Cutech S.r.l. Compositions comprising MAO inhibitors for treatment of disorders of hair follicles. EP2033687; 2009
123. Lines TC. Composition comprising inhibitors of serotonin, monoamine oxidase, and phosphodiesterase for treating mental health disorders. WO2006091988; 2006
124. Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising combinations of droxidopa with catechol-O-methyltransferase inhibitors, cholinesterase inhibitors, or monoamine-oxidase inhibitors, for treating conditions such as orthostatic hypotension. WO2008003028; 2008
125. Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders. WO2008137923; 2008
126. Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovas Drug Rev 2006;24(3-4):189-203
127. Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction. WO2009137733; 2009
128. Ellneuroxx, Ltd. Synthesis of dihydroxyphenylalanine derivatives for use in treatment of brain disorders. WO2006119758; 2006
129. Janssen Pharmaceutica, N.V. Phenylalaninol carbamate compound adjunctive therapy for depression. WO2006050037; 2006
130. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-215
131. Medivation, Inc. Methods and combination therapies for treating Alzheimer's disease. WO2008051599; 2008
132. Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a NSRI (norepinephrine serotonin reuptake inhibitors), a SNRI (serotonin norepinephrine reuptake inhibitors) or a RIMA (reversible inhibitors of monoamine oxidase A) by using them in combination. WO2009023820; 2009
133. The University of Montana, USA. Method using a central nervous system stimulant, monoamine neurotransmitter, monoamine oxidase inhibitor, or tricyclic antidepressant for reducing neuronal cell damage caused by transient cerebral hypoxia and/or ischemia. WO2008024660; 2007
134. Janssen Pharmaceutica, N.V. Treatment of sexual dysfunction with amino(phenyl)alkyl carbamates. WO2007001841; 2007
135. Foreman MM. Disorders of sexual response: pioneering new pharmaceutical and therapeutic opportunities. Exp Opin Invest Drugs 1995;4:621-636
136. Richter Gedeon Vegyeszeti Gyar Rt. Pharmaceutical combinations of voltage-gated sodium channel blockers and monoamine oxidase B inhibitors. WO2007060491; 2007
137. Clare JJ, Tate SN, Nobbs M, Romanos MA. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 2000;5:506-520
138. Chongqing Pharmaceutical Research Institute Co., Ltd. Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process. WO2007101400; 2007
139. Newron Pharmaceuticals S.p.A. Process for the production of highly pure 2-[4-(3- or 2-fluorobenzyloxy) benzylamino]propanamides as cytochrome P450 inhibitors and their pharmaceutical compositions and use in the treatment of diseases. WO2009074478; 2009
140. Pevarello P, Bonsignori A, Dostert P. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanide derivatives. J Med Chem 1998;41:579-590
141. Anup K, Upadhyay, Jin Wang, Dale E. Edmondson comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms. Biochemistry 2008;47:526-536
142. Novaroli L, Daina A, Favre E, et al. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J Med Chem 2006;49:6264-6272